Day: August 3, 2021

DURHAM, N.C., Aug. 03, 2021 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a panel discussion at the 2021 Wedbush PacGrow Healthcare Conference on Tuesday, August 10, 2021 at 10:55 a.m. ET. An audio webcast of the panel discussion will be available on the Investor Relations section of Chimerix’s website at ir.chimerix.com, where it will be archived for approximately 90 days. About Chimerix Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. In June 2021,...

Initial Focus on MEAI Clinical Trial Protocol Toronto, Aug. 03, 2021 (GLOBE NEWSWIRE) —  Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, announces that Mark Haden has joined the Company’s Scientific Advisory Board (the “SAB”). The SAB’s initial focus will be providing guidance on the Company’s request for an Investigational New Drug review from the US Food and Drug Administration (“FDA”) for MEAI, for treating Alcohol Use Disorder (“AUD”). A recognized leader in the field, Mr. Haden has spent his career working to advance the use of psychedelics in medicine. He currently serves as director of clinical research at Psygen Industries,...

Company to Host Quarterly Conference Call at 11:00 AM ET Today WALTHAM, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) — Great Elm Capital Corp. (“we,” “us,” “our,” or “GECC,”) (NASDAQ: GECC), a business development company, today announced its financial results for the second quarter and six months ended June 30, 2021. Financial and Operating HighlightsNet investment income (“NII”) for the quarter was $2.1 million, as compared to NII of $1.5 million for the quarter ended March 31, 2021, and $0.9 million for the quarter ended June 30, 2020. NII increased quarter-over-quarter due to accelerated deployment of capital during the prior quarter. NII per share was $0.09 based on weighted average shares outstanding of 23,508,232 for the quarter ended June 30, 2021, as compared to NII per share of $0.06, based on weighted average shares outstanding...

REDWOOD CITY, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to chronic glucose imbalance, today announced that Nevan Charles Elam, CEO and Founder, will present at two upcoming virtual investment conferences.BTIG Virtual Biotechnology Conference – Tuesday, August 10, 2021 at 12:00 p.m. ET, fireside chat   Canaccord Genuity 41st Annual Growth Conference – Thursday, August 12, 2021 at 3:30 p.m. ET, fireside chatA live webcast of the Canaccord Genuity presentation will be available on the “IR Calendar” page within the Investors section of the Rezolute website at https://ir.rezolutebio.com/ir-calendar. A replay of the webcast will be archived for 90 days following the presentation date. About Rezolute,...

MORRISVILLE, N.C., Aug. 03, 2021 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its second quarter 2021 financial results on Tuesday, August 10, 2021. The company will host a webcast and conference call at 8:30 a.m. Eastern Daylight Time to discuss financial results and provide a corporate update. The live call may be accessed by dialing 1-877-707-8711 (domestic) or 1-857-270-6219 (international) and entering the conference code: 4638099. A webcast of the call will be available and archived on Liquidia’s website at https://liquidia.com/index.php/investors/events-and-presentations. About Liquidia CorporationLiquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology....

Global Transformation Efforts Resulted in Constellation Research Award for 2022 ATLANTA, Aug. 03, 2021 (GLOBE NEWSWIRE) — First Advantage (NASDAQ: FA), a leading global provider of technology solutions for screening, verifications, safety, and compliance related to human capital, today shared that the company’s Chief Experience Officer, Joelle Smith, was recently recognized by Constellation Research’s 2022 Business Transformation 150, an elite list of executives who are leading their organization’s business transformation efforts around the globe. With digital leaders significantly challenged by a perfect storm of disruptions due to COVID-19, generational shifts in the workforce, a hypercompetitive customer experience landscape and the relentless march of digital change, among other factors, the BT150 nomination process took these...

Reports Record Second Quarter Revenue and Profit FREMONT, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) — Corsair Gaming, Inc. (NASDAQ:CRSR) (“Corsair”), a leading global provider and innovator of high-performance gear for gamers and content creators, today announced financial results for the second quarter ended June 30, 2021. Second Quarter 2021 HighlightsNet revenue was $472.9 million, an increase of 24.3% year-over-year. Gamer and creator peripherals segment net revenue was $155.2 million, an increase of 40.9% year-over-year. Gaming components and systems segment net revenue was $317.7 million, an increase of 17.6% year-over-year. Gross profit was $130.4 million, an increase of 24.1% year-over-year, with gross margin of 27.6%, flat year-over-year. Gamer and creator peripherals segment gross profit was $54.6 million, an increase...

— Pivotal Phase 3 EMANATE trial planned in patients with heterozygous POMC, PCSK1 or LEPR, and SRC1 or SH2B1 deficiency obesities —— EMANATE, as well as Phase 2 DAYBREAK trial evaluating setmelanotide in 31 new genes, Phase 3 pediatrics trial and Phase 3 trials of weekly setmelanotide formulation all expected to initiate in 2H 2021 —— Updated Uncovering Rare Obesity genetic test with expanded gene panel launched in July — — Company to host conference call at 8 a.m. ET today — CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced a significant expansion of its clinical development program for setmelanotide...

~ Successful Mount Holly integration contributed favorably to Q2 results ~ Acquisition of Jacob Holm will add scale and new technologies, enhancing engineered materials portfolio CHARLOTTE, N.C., Aug. 03, 2021 (GLOBE NEWSWIRE) — Glatfelter Corporation (NYSE: GLT), a leading global supplier of engineered materials, today reported net income for the three months ended June 30, 2021 of $1.5 million, or $0.03 per diluted share, compared with a loss of $2.3 million, or a loss of $0.05 per share, in the same period a year ago. The results include the acquisition of Georgia-Pacific’s U.S. nonwovens business (“Mount Holly”) effective May 13, 2021. Adjusted earnings from continuing operations for the three months ended June 30, 2021 and 2020, were $8.0 million, or $0.18 per share, compared with $9.9 million, or $0.22 per share, respectively....

Inter Pipeline Ltd. (“IPL”) shareholders must tender their shares by August 6th to receive the significant premium available under Brookfield Infrastructure’s Offer to purchase the company The IPL Board of Directors have recommended that IPL shareholders accept the Offer from Brookfield Infrastructure Offer represents a 50% premium to IPL’s unaffected share price1 and has received all key regulatory and financing approvals with the ability to close within three business days of the Offer expiry (subject to the modified statutory minimum condition) Shareholders may elect up to 100% cash consideration, totalling C$20.00 per share of IPL without being subject to proration or 0.250 of a class A exchangeable subordinated voting share of Brookfield Infrastructure Corporation (a “BIPC Share”), subject to proration Questions or Need Assistance?...